Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 1,947 shares of Castle Biosciences stock in a transaction dated Friday, April 12th. The shares were sold at an average price of $20.35, for a total value of $39,621.45. Following the completion of the sale, the insider now owns 65,418 shares of the company's stock, valued at $1,331,256.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Castle Biosciences Trading Down 0.5 %
Shares of CSTL opened at $18.84 on Thursday. Castle Biosciences, Inc. has a 12 month low of $9.26 and a 12 month high of $26.70. The stock has a fifty day moving average price of $21.71 and a 200-day moving average price of $19.83. The firm has a market cap of $517.16 million, a PE ratio of -8.72 and a beta of 0.93.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last issued its quarterly earnings results on Wednesday, February 28th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.74. The business had revenue of $66.12 million during the quarter, compared to the consensus estimate of $51.32 million. Castle Biosciences had a negative return on equity of 14.92% and a negative net margin of 26.15%. As a group, research analysts forecast that Castle Biosciences, Inc. will post -2.41 EPS for the current year.
Institutional Investors Weigh In On Castle Biosciences
READ THIS – If You Missed Out On The AI Boom
From Banyan Hill Publishing | Ad
Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy.
Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”
Click on Adam's shiny forehead for more details.
Several institutional investors and hedge funds have recently made changes to their positions in CSTL. BluePath Capital Management LLC purchased a new position in Castle Biosciences in the 3rd quarter worth $31,000. Royal Bank of Canada raised its stake in shares of Castle Biosciences by 40.5% in the second quarter. Royal Bank of Canada now owns 2,880 shares of the company's stock worth $39,000 after purchasing an additional 830 shares during the last quarter. O Dell Group LLC acquired a new stake in shares of Castle Biosciences during the fourth quarter worth about $44,000. Tower Research Capital LLC TRC boosted its position in Castle Biosciences by 61.2% in the third quarter. Tower Research Capital LLC TRC now owns 1,821 shares of the company's stock valued at $47,000 after buying an additional 691 shares during the last quarter. Finally, Osaic Holdings Inc. increased its holdings in Castle Biosciences by 37.2% in the 2nd quarter. Osaic Holdings Inc. now owns 3,626 shares of the company's stock worth $50,000 after buying an additional 984 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several equities research analysts have recently weighed in on the stock. Scotiabank upped their price target on shares of Castle Biosciences from $33.00 to $37.00 and gave the stock a "sector outperform" rating in a research report on Friday, March 1st. KeyCorp increased their target price on Castle Biosciences from $25.00 to $28.00 and gave the company an "overweight" rating in a research report on Friday, March 1st.
Read Our Latest Research Report on CSTL
About Castle Biosciences
(
Get Free Report)
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
